Caspases are an evolutionary conserved family of cysteine-dependent proteases that are involved in many vital cellular processes including apoptosis, proliferation, differentiation and inflammatory response. Dysregulation of caspase-mediated apoptosis and inflammation has been linked to the pathogenesis of various diseases such as inflammatory diseases, neurological disorders, metabolic diseases, and cancer. Multiple caspase inhibitors have been designed and synthesized as a potential therapeutic tool for the treatment of cell death-related pathologies. However, only a few have progressed to clinical trials because of the consistent challenges faced amongst the different types of caspase inhibitors used for the treatment of the various pathologies, namely an inadequate efficacy, poor target specificity, or adverse side effects. Importantly, a large proportion of this failure lies in the lack of understanding various caspase functions. To overcome the current challenges, further studies on understanding caspase function in a disease model is a fundamental requirement to effectively develop their inhibitors as a treatment for the different pathologies. Therefore, the present review focuses on the descriptive properties and characteristics of caspase inhibitors known to date, and their therapeutic application in animal and clinical studies. In addition, a brief discussion on the achievements, and current challenges faced, are presented in support to providing more perspectives for further development of successful therapeutic caspase inhibitors for various diseases.

Ge···ic···st···li···un···li···ge···is···d ··· d···lo···nt··· v···ou···yp···of···nc··· D···ng···mo···en···s,···nc···in···at··· c···s ···um··· s···of···at···s,···ic···ll···th···to···rv··· a···pr···fe···e.···ff···nt···ta···ns···d ···om···ma···lt···ti··· p···ot··· s···ct··· o···he···st···gr···iv···an··· c···es···at···rs···th···ro···si···f ··· d···as···De···te···at···sp···-2···s ···cr···d ···a ···te··· f···il···g ···in···at···an···n ···ec··· f···ti···in···op···is···t ··· r···nt···be···di···ve··· t···la···n ···or···t ···e ···th···ai···na··· o···en···c ···eg···y ··· n···al···ro···om···on···ur···on···hi···ro···n ···ab···to···ab···ze···3 ··· a···ct···e ···el··· t···sc···ti···fa···rs···hi···ac···at···ce···re···ns···o ···da···e ···es···He···we···cu···n ··· d···us···n ···th···ec···is···) ···ho···as···e-···eg···te···en···c ···bi···y ··· d···ea··· t···ri···es···

Genomic instability underlies genesis and the development of various types of cancer. During tumorigenesis, cancer initiating cells assume a set of features, which allow them to survive and proliferate. Different mutations and chromosomal alterations promote a selection of the most aggressive cancer clones that worsen the prognosis of the disease. Despite that caspase-2 was described as a protease fulfilling an initiator and an effector function in apoptosis, it has recently been discovered to play an important role in the maintenance of genomic integrity and normal chromosome configuration. This protein is able to stabilize p53 and affect the level of transcription factors, which activates cell response to oxidative stress. Here we focus on the discussion on the mechanism(s) of how caspase-2 regulates genomic stability and decreases tumorigenesis.

An···er···g ···e ···lo···no···od··· R··· (···RN··· i···um···pr···es···n ··· b··· r···al···in···e ···t ···ad···Th···gh···te···ti··· w··· n···ei···ci···an···ro···ns···nc···s ···ld···t ···en···ce··· s···fo··· o···ec··· f···a ···be···f ···op···ei···an···um···su···es···s.···e ···rr··· l···NA···pr···io···r ···at···s ··· o···n ···oc···ed···th···an··· i··· v···et···f ···lu··· p···es···, ···lu···g ···li···at···, ···es···es···se···d ···l ···th···er···we···ll···cu···n ··· t···r-···oc···ed···cR··· i···va···n ···ce···cc···in···o ···ir···nt···ut··· t···an··· h···ma···, ···h ···in···se···ol···ra···n,···ll···at···es···an··· a···re···ne··· m···bo···m,···va···n ··· m···st···s,···d ···un···va···n.···re···r,···e ···en···l ···ni··· i···ic···on···f ···RN···an···he···si···fi···ce···r ··· d···no···, ···gn···s ··· t···ap···f ···ri···ca···r ···l ···di···ss···

An emerging role of long non-coding RNAs (lncRNAs) in tumor progression has been revealed in the last decade. Through interactions with nucleic acids and proteins, lncRNAs could act as enhancers, scaffolds or decoys for a number of oncoproteins and tumor suppressors. The aberrant lncRNA expression or mutations are often associated with changes in a variety of cellular processes, including proliferation, stress response and cell death. Here, we will focus on the tumor-associated lncRNAs in ovarian cancer according to their contribution to cancer hallmarks, such as intense proliferation, cell death resistance, altered energy metabolism, invasion and metastasis, and immune evasion. Moreover, the potential clinical implications of lncRNAs and their significance for the diagnosis, prognosis and therapy of ovarian cancer will be discussed.

Su···ll···r ···ct···at··· a···oa···s ···ai···n ···is···sa··· t··· a···g ···ar···nu···r ···bi···em···l ···ho···to···ci···at···he···ud···f ···ci··· i···ac···ul···ev···s ··· c···ac···iz···on··· p···ei···un···on···Du···g ···pt···s,···e ···t-···wn···rm··· p···ra···d ···l ···th···um···us···ot···s ··· t···sl···te···nt···nd···om···e ···le··· T···ef···, ···ta··· b···he···al···ch···ue···or···e ···ce···la···ra···on···on··· a···to··· c···s ··· r···ir··· H···ve···ap···ot···bo···s ··· c··· f···me··· m···t ···ta···at···he···ac···ns···on···in···he···an···d ···to···s.···re···e ···pa··· d···er··· n···eu···yt···as···ra···on···on···th··· a···se···te···he···st···it···ap···ac···or···e ···ar···on··· n···ea···nd···to···sm···co···nt···Th···es···be···et···ol··· i···as···on···ep···e ···is··· c···s ··· w···in···f ··· r···lt··· n···ei···in···on···ni···et···en··· s··· a···P-··· N···, ···va···at···th···ap···ac···or···ac···na···n ···ce··· t···te···it···ar···s ···pt···c ···mu··· F···ll···we···mo···ra··· t··· n···ea···ra···on···ul···e ···th···su···vi··· i··· n···eo···ic···d ···ol···e ···fr···io··· w···h ···cr···al···r ··· i···at··· a···fu···io··· s···ie···f ···io···pr···in···Al···et···, ···de···op···a ···ho···or···mp···an···ff···en···uc···s/···op···m ···ct···at··· o···ot···or··· a···ap···ot···ce···.

Cancer therapy is aimed at the elimination of tumor cells and acts via the cessation of cell proliferation and induction of cell death. Many research publications discussing the mechanisms of anticancer drugs use the terms "cell death" and "apoptosis" interchangeably, given that apoptotic pathways are the most common components of the action of targeted and cytotoxic compounds. However, there is sound evidence suggesting that other mechanisms of drug-induced cell death, such as necroptosis, ferroptosis, autophagy, etc. may significantly contribute to the fate of cancer cells. Molecular cross-talks between apoptotic and nonapoptotic death pathways underlie the successes and the failures of therapeutic interventions. Here we discuss the nuances of the antitumor action of two groups of the widely used anticancer drugs, i.e., platinum salts and taxane derivatives. The available data suggest that intelligent interference with the choice of cell death pathways may open novel opportunities for cancer treatment.

Cancer therapy is aimed at the elimination of tumor cells and acts via the cessation of cell proliferation and induction of cell death. Many research publications discussing the mechanisms of anticancer drugs use the terms "cell death" and "apoptosis" interchangeably, given that apoptotic pathways are the most common components of the action of targeted and cytotoxic compounds. However, there is sound evidence suggesting that other mechanisms of drug-induced cell death, such as necroptosis, ferroptosis, autophagy, etc. may significantly contribute to the fate of cancer cells. Molecular cross-talks between apoptotic and nonapoptotic death pathways underlie the successes and the failures of therapeutic interventions. Here we discuss the nuances of the antitumor action of two groups of the widely used anticancer drugs, i.e., platinum salts and taxane derivatives. The available data suggest that intelligent interference with the choice of cell death pathways may open novel opportunities for cancer treatment.

BH···im···cs···pr···nt···pr···si···to···in···nc···tr···me··· R···nt··· t···dr··· t···et··· t···Mc··· p···ei···ro···ss···in···cl···ca···ri···, ··· n···ro···st···es···e ···us···on···e ···es···at··· o···he···ac···it···n ···io···pr···in···l ···el···We···ve···ga··· t···BH···im···cs··· M···1,···21···7 ··· S···45···nd···un···he···di···re···ef···ac··· i···n-···ge···os··· d···it···he···m>···t<···> ···t ···h ···nt···nt···ct···wi···th···ar···. ···s,···38···in···ed···op···is···re···fe···ve···th···gh···Ba···ep···en···ec···is···Th··· w···an···cr···e ···th···ev···of···l-···pr···in··· c···s ···h ···ui··· r···st···e ···Mc··· i···bi···n.···ll···ne···en···iv···o ···84···em···tr···d ··· e···es···n ···Bc···L.···mo···is···s ···m ···ie··· w··· l··· a···oc···in··· w··· c···ac···iz···by···cr···ed···l-···an···nc···se···ak···ve···of···th···NA···d ···te···. ···co···an···nh···ti···of···l-···an···cl···de···st···ed···am···c ···ot···ci···in···x ···se··· s···ie···el···in··· W···ro···ed···at···-t···et··· B···xL···d ···-1···gh···ea···o ···el···e ···Ba···wh··· c···ot··· n···ra···ed··· o···r ···i-···pt···c ···te···. ···pr···ng··· i···ak···oc···t ···ls···nh···ti···of···l-···nd···l-···st··· r···lt···in···on···ce···el···ea··· a···in···ga···t ···ol···ol···f ··· i···he···ud··· p···om···n.··· d···ns···te···at···k ··· B···xL···e ···fa···rs···r,···sp···iv···, ···si···it···nd···si···nc···o ···-1···hi···io··

Fo···ve···0 ···rs···t ··· b··· a···gm···ha···nc···he···te···ty··· m···ch···ri···s ···ru···d ··· p···po···ti···ro···ns···at···e ···ma··· l···te···n ··· i···rm···ra···sp··· o···it···on···a ···ea··· i···he···to···sm···he···oc··· o···el···ea···be···es···ev···bl···Ho···er···t ··· b··· r···nt···sh··· t··· u··· r···va···f ··· d···h ···na···ev···at···e ···ge··· d···ur···ce··· t···mi···ho···ia···el···ca···ec···r ··· c···in···to···ow···hi···he···en···wa···am···an···as··· H···, ···wi···cr···ca··· d···us···he···es··· k···le··· c···er···g ··· m···an···s ···ce···de··· r···rs··· o···ev···pm··· o···na···si···me···ds···r ··· d···ct···, ··· w··· r··· s···al··· f··· d···er··· i···ac···ul···co···rt···ts···ay···n ···st···s ···mu···io··